News

Although, the FDA is not obliged to go by the recommendation of the committee, more often or not it takes its advice into consideration. The drug, which is

A venture-backed biotech company, IFM Therapeutics is into developing therapies that regulate novel targets in the innate immune system for the treatment of cancer, autoimmunity and inflammatory disorders.

CEO of Orbsen Therapeutics, Dr Larry Couture, commented: “This approval is an important step toward the clinical demonstration of the tremendous potential of Orbsen’s ‘off-the-shelf’ allogeneic ORBCEL-M second

The NDA is based on results from the Phase II ACE-LY-004 clinical trial, which evaluated the safety and efficacy of acalabrutinib in patients with relapsed/refractory mantle cell lymphoma

Marketed as Tecentriq, atezolizumab was assessed by NICE as a treatment option for patients with advanced urothelial cancer. The UK drug watchdog has suggested Roche to file a

The COMMEND trial will evaluate FLX-787, the Company’s co-activator of TRPA1 and TRPV1, in patients with motor neuron disease (MND), focused on ALS, who suffer from painful, debilitating

The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial. The combination of AE37 plus KEYTRUDA follows previous studies, in which both

Opdivo which has to be injected intravenously has been approved for treating mCRC patients whose disease is in the microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) form.

This application represents the first chimeric antigen receptor (CAR) T-cell therapy submitted to the EMA. Axicabtagene ciloleucel is currently under review by the U.S. Food and Drug Administration